Prior Authorization Reform for Autoimmune and Blood Disorders Act
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Email me when HR 9192 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track HR 9192. By continuing you agree to the Terms and Privacy Policy.
Legislative status
- Introduced
- In Committee
- Reported by Committee
- Floor Vote Scheduled
- Passed One Chamber
- Passed Both Chambers
- Sent to Executive
- Signed into Law
Summary
The bill forces group health plans and health insurers to cover any drug used to treat autoimmune diseases, hemophilia, or Von Willebrand disease, no matter how the drug is provided. It also bars them from requiring more than one prior‑authorization request for the same drug within a 12‑month period, except for short‑term treatments, certain controlled substances, or drugs that have a federal risk‑evaluation requirement. The goal is to speed patient access and cut administrative burdens.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about HR 9192
3 free questions a day, no accountSponsors
- Rep. Johnson, Julie [D-TX-32] (D) · sponsor
Similar bills in other states
Loading the map of where bills like this one were filed.
Topics
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when HR 9192 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track HR 9192 freeOr ask your AI assistant about HR 9192 directly:
Add to Claude, ChatGPT or Cursor